Twice-Yearly HIV Prevention Shot Prevented Infections in Major Trial
In the PURPOSE 1 phase 3 trial in South Africa and Uganda, no HIV infections occurred among 2,134 participants assigned to twice-yearly lenacapavir injections. The result suggests long-acting prevention could…